| Drug Type Monoclonal antibody | 
| Synonyms LM 102, LM102 | 
| Target | 
| Action inhibitors | 
| Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 1/2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China  | 06 Oct 2021 | |
| CLDN18.2 positive Solid Tumors | Phase 2 | China  | 06 Oct 2021 | |
| Bile Duct Neoplasms | IND Approval | China  | 27 Oct 2022 | |
| Pancreatic Cancer | IND Approval | China  | 27 Oct 2022 | |
| Stomach Cancer | IND Approval | China  | 27 Oct 2022 | |
| Solid tumor | IND Approval | China  | 12 Jun 2021 | 






